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Résumé en
anglais
Cryptosporidiosis is a common disease in children and immunodeficient individuals. In
2006, a national network was set up on the surveillance of human cryptosporidiosis in
France. Since January 2015, the 41 tertiary care hospitals and the 3 private
laboratories of the French National Network on the surveillance of human
cryptosporidiosis have been able to declare confirmed cases of cryptosporidiosis
online. Between 2015 and 2017, 210 cases of cryptosporidiosis were declared in
immunodeficient patients in France; Cryptosporidium parvum and Cryptosporidium
hominis represented 66% and 22% of cases, respectively. A peak was observed in
autumn. Cryptosporidiosis occurred mainly in a context of solid organ transplantation
(SOT) (49%) and of HIV infection (30%). In SOT recipients, cryptosporidiosis appeared
more frequently in the first 6 months post transplantation. Regarding cases declared in
SOT recipients, mycophenolate mofetil was used in 68%. A mortality rate of 6% was
observed. Present results underline the importance of screening for cryptosporidiosis
in immunocompromised patients suffering from diarrhea, especially in the course of
major cell mediated immunodeficiency or even systematic screening before SOT.
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